Trispecific T cell Engagers

ANTIBODIES AGAINST HUMAN CD38

BINDING PROTEINS AND METHODS OF USE THEREOF

CONSTRUCTION METHOD FOR HUMANIZED ANTIBODY SEQUENCE EVALUATION MODEL AND USE THEREOF

IMMUNOLOGIC AGENT AGAINST CANINE MALIGNANCY

Multi Variable Domain Therapeutic Immunoglobulin

CD3-TARGETING ANTIBODY AND USE THEREOF

AGONISTIC ANTIBODIES THAT BIND HUMAN CD40 AND USES THEREOF

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS

ANTI-CD137 ANTIBODIES

COMBINATION THERAPY WITH FAP-TARGETED LYMPHOTOXIN BETA RECEPTOR AGONISTS

Amino Acid Sequences Directed Against the Melanocortin 4 Receptor and Polypeptides Comprising the Same for the Treatment of MC4R-Related Diseases and Disorders

TIE2-BINDING AGENTS AND METHODS OF USE

ANTI-CD40 ANTIBODY CONSTRUCTS WITH HIGH INTRINSIC AGONISM

ANTI-CD157 ANTIBODIES, ANTIGEN-BINDING FRAGMENTS THEREOF AND COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME

AGONISTIC TNF RECEPTOR BINDING AGENTS

MULTISPECIFIC CONSTRUCTS AND USES THEREOF

TREM-2 AGONISTS FOR THE TREATMENT OF MARFAN SYNDROME

CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

MULTI-DOMAIN BINDING MOLECULES

ANTI-PD-1 ANTIBODIES

PD-1 AGONIST ANTIBODIES AND METHODS OF TREATING AUTOIMMUNE DISEASES WITH A PD-1 AGONIST ANTIBODY

MODULATORS

CD40L 41BBL BISPECIFIC PROTEINS

BISPECIFIC T CELL ENGAGERS

METHODS AND COMPOSITIONS FOR TREATING AUTOIMMUNE, ALLERGIC AND INFLAMMATORY DISEASES

TREM2 BINDS TO SPECIFICALLY STRUCTURED HEPARAN SULFATE

Anti-MuSK Agonistic Antibodies

BISPECIFIC ANTIBODY BINDING TO TNFR2 AND 4-1BB

BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)

MULTISPECIFIC ANTIBODY WITH COMBINATION THERAPY FOR IMMUNO-ONCOLOGY

MULTIFUNCTIONAL MOLECULE DIRECTED AGAINST CD28

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

Modified IgG1 Fc Domains and Anti-CD40 Domain Antibody Fusions Therewith

ANTI-IL1RAP ANTIBODIES AND METHODS OF USE THEREOF

ANTIGEN-BINDING MOLECULE CONTAINING TWO ANTIGEN-BINDING DOMAINS THAT ARE LINKED TO EACH OTHER

MEDICAMENTS, USES AND METHODS

ANTI-TREM2 AGONIST ANTIBODIES AND ANTIGEN-BINDING FRAGMENTS THEREOF THAT CAN INCREASE LEVELS OF SOLUBLE TREM2 IN SERUM AND BRAIN TISSUE

Retroviral and Lentiviral Vectors

FGF21 MIMETIC ANTIBODIES AND USES THEREOF

ANTI-CD137 ANTIGEN-BINDING MOLECULE AND UTILIZATION THEREOF

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

BISPECIFIC FACTOR VIII MIMETIC ANTIBODIES

STRATEGY FOR HIGHLY SUPERIOR DR5 ACTIVATION INCLUDING IN TUMORS AND CANCERS

ANTI-CD28 ANTIBODIES

MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES

New Interleukin-7 Immunoconjugates

ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

Methods and Compositions Relating to GLP1R Variants

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

Methods for Manipulating Phagocytosis Mediated by CD47

ACTIVATING ANTIBODIES OF RECEPTOR PROTEINS PLXDC1 AND PLXDC2

POLYPEPTIDE VARIANTS AND USES THEREOF

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

ANTI-TNFR2 ANTIBODY AND PREPARATION METHOD AND APPLICATION THEREOF

INTERFERON-ASSOCIATED ANTIGEN BINDING PROTEINS FOR USE FOR THE TREATMENT OR PREVENTION OF CORONAVIRUS INFECTION

METHODS OF TREATMENT USING A LEPTIN RECEPTOR AGONIST ANTIBODY

CD137 ANTIBODIES AND PD-1 ANTAGONISTS AND USES THEREOF

WNT SIGNALING AGONIST MOLECULES

ANTI-BTLA ANTIBODIES AND USES THEREOF IN TREATING CANCER

COMPOSITIONS AND METHODS FOR MODULATING IMMUNE RESPONSES

INTEGRIN ALPHA-7 BETA-1 ANTIBODIES AND USES THEREOF

B AND T LYMPHOCYTE ATTENUATOR (BTLA) MODULATORS AND METHOD OF USING SAME

TREATMENT OF DISEASES RELATED TO ATP-BINDING CASSETTE TRANSPORTER 1 DYSFUNCTION USING TREM2 AGONISTS

ANTIBODY-BASED SOLUBLE AND MEMBRANE-BOUND TWEAK MIMICKING AGONISTS WITH FCYR-INDEPENDENT ACTIVITY

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

ANTIBODIES FOR T-CELL ACTIVATION

IMMUNE CELL INHIBITION BY IMMUNE CHECKPOINT ENGAGERS

ANTI-IGF-1 RECEPTOR HUMANIZED ANTIBODY

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF

BISPECIFIC BINDING AGENT

ATP-Dependent Agonists of Immune Cells Function as Anticancer Agents

BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)

ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF

USES OF PDL1-BINDING PROTEINS

METHODS FOR CONTROLLING THE TUMOR CELL KILLING BY LIGHT

ENGRAFTMENT OF STEM CELLS WITH A COMBINATION OF AN AGENT THAT TARGETS STEM CELLS AND MODULATION OF IMMUNOREGULATORY SIGNALING

AGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR 2 ANTIBODIES

ENHANCING ANTI-CANCER ACTIVITY OF IMMUNOMODULATORY FC FUSION PROTEINS

ANTI-CD40 ANTIBODIES AND USES THEREOF

PLXDC1/PLXDC2 ACTIVATORS AND THEIR USE IN THE TREATMENT OF BLOOD VESSEL DISORDERS

MULTISPECIFIC BINDING PROTEINS THAT BIND DECTIN-1 AND CD20 AND METHODS OF USE THEREOF

ANTI-SIRPa ANTIBODIES AND THEIR THERAPEUTIC APPLICATIONS

MULTISPECIFIC NK ENGAGER PROTEIN

TREM2 STABILIZING ANTIBODIES

ANTIBODIES SPECIFICALLY BINDING PD-1, TIM-3 OR PD-1 AND TIM-3 AND THEIR USES

RNA CONTAINING COMPOSITION FOR TREATMENT OF TUMOR DISEASES

MANUFACTURING PROCESSES FOR ADOPTIVE CELL THERAPIES

TRAILshort ANTIBODY AND METHODS OF USE

ANTI-LAG-3 ANTIBODIES TO TREAT HEMATOLOGICAL MALIGNANCIES

LAG-3 AGONIST ANTIBODIES

IN UTERO TREATMENT OF A FETUS HAVING GENETIC DISEASE/NEUROMUSCULAR DISEASE

ANTI-CD137 ANTIBODIES AND METHODS OF MAKING AND USING THE SAME

TGF-ß ANTIBODIES

COMBINING CD27 AGONISTS AND IMMUNE CHECKPOINT INHIBITION FOR IMMUNE STIMULATION

NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP

ANTIBODIES WITH FC MODIFICATIONS AND METHODS OF USING THE SAME

HETEROMERIC AGONISTIC ANTIBODIES TO IL-18 RECEPTOR

Anti-SIRPa Antibodies and Methods of Use Thereof

ANTI-CD160 TRANSMEMBRANE ISOFORM ANTIBODIES

ANTIBODY, NUCLEIC ACID, CELL, AND PHARMACEUTICAL

NOVEL ANTIBODIES AND ANTIBODY CONJUGATES FOR THE TREATMENT OF METABOLIC DISORDERS

COMPOSITIONS AND METHODS RELATED TO RECEPTOR PAIRING

Human Antigen Binding Proteins That Bind Beta-Klotho, FGF Receptors and Complexes Thereof

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1

ANTI-TRANSFERRIN RECEPTOR ANTIBODIES WITH TAILORED AFFINITY

Antibodies that Bind CD3 Epsilon

CD137 AGONIST ANTIBODIES AND USES THEREOF

ANTI-PD-L1/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOF

Anti-SIRP-Alpha Antibodies and Methods of Use Thereof

ANTI-CD73 ANTIBODIES AND USE THEREOF

ANTIBODIES TO PROGRAMMED CELL DEATH PROTEIN 1 THAT ARE PD-1 AGONISTS

ANTI-HUMAN CD3 ANTIBODY AND USE THEREOF

TREM2 STABILIZING ANTIBODIES

OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF

BUTYROPHILIN (BTN) 3A ACTIVATING ANTIBODIES FOR USE IN METHODS FOR TREATING INFECTIOUS DISORDERS

BISPECIFIC ANTIBODY AND USE THEREOF

AGONIST FUSION PROTEIN FOR CD40 AND OX40 AND USES THEREOF

AGONISTIC ANTIBODIES THAT BIND CD40

HUMAN ANTIBODIES TO PD-L1

COMPOSITIONS AND METHODS FOR THE MODULATION OF BETA CHAIN-MEDIATED IMMUNITY

Anti-TREM1 Antibodies and Methods of Use Thereof

PHARMACEUTICAL COMPOSITION OR DRUG KIT FOR ALLEVIATING OR TREATING FIBROTIC DISEASES, AND USE THEREOF

VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

AGONISTIC ANTI TNFR2 ANTIBODY MOLECULES

ANTI-EGFR/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF

TREATMENT OF CANCER WITH COMBINATIONS OF IMMUNOREGULATORY AGENTS

TIGIT AND CD112R BLOCKADE

AGONISTIC CD28 ANTIGEN BINDING MOLECULES TARGETING HER2

CD27 AGONISTS

FAP/CD40 BINDING MOLECULE AND MEDICINAL USE THEREOF

ANTIGEN-BINDING PROTEINS THAT ACTIVATE THE LEPTIN RECEPTOR

BISPECIFIC ANTI-VEGF AND ANTI-TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASES

NON-CYTOTOXIC MODIFIED CELLS AND USE THEREOF

USE OF BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND MUC16 AND CD3 IN COMBINATION WITH 4-1BB CO-STIMULATION

LOW ENERGY IMMUNE PRIMING FOR TREATING CANCER AND METASTASIS

METHODS OF EFFECTING A HEMODYNAMIC CHANGE BY ADMINISTERING AN ANTI-NPR1 ANTIBODY

AGONISTIC LTBR ANTIBODIES AND BISPECIFIC ANTIBODIES COMPRISING THEM

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

ADENOVIRUS ARMED WITH BISPECIFIC T CELL ACTIVATOR

MODIFIED PROTEIN OR POLYPEPTIDE

Anti-SIRP-Beta1 Antibodies and Methods of Use Thereof

BISPECIFIC AGONISTIC ANTIBODIES TO IL12 RECEPTOR

AGENTS THAT ENGAGE ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL ASIALOGLYCOPROTEIN RECEPTOR (DC-ASGPR)

ANTIBODIES AND METHODS OF USE

Procoagulant Antibodies

DYSFUNCTIONAL ANTIGEN-SPECIFIC CD8+ T CELLS IN THE TUMOR MICROENVIRONMENT

ANTIBODIES AND USES THEREOF

WNT SIGNALING AGONIST MOLECULES

ANTI-CD122 ANTIBODIES, ANTI-CD132 ANTIBODIES, AND RELATED BISPECIFIC BINDING PROTEINS

BISPECIFIC AGONISTIC ANTIBODIES TO ACTIVIN A RECEPTOR LIKE TYPE 1 (ALK1)

TARGETED IMMUNOTOLERANCE WITH A PD-1 AGONIST

Trispecific T cell Engagers

SINGLE DOMAIN ANTIBODIES TARGETING CD1D

Anti-pd-1 antibody-attenuated IL-2 immunoconjugates and uses thereof

Albumin Bound Macromolecule Tri-Agonist Activating GLP-1/GIP/Glucagon Receptors

Albumin Bound Macromolecule Tri-Agonist Activating GLP 1/GIP/Glucagon Receptors And Methods Therefor

NOVEL COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE RELATED DISEASES

MOLECULES THAT BIND TO CD94/NKG2A HETERODIMER POLYPEPTIDES

Polypeptides That Bind to von Willebrand Factor (VWF) A1 Domain or an Autoinhibitory Module, Variants, and Uses Thereof

ANTI-OX40 ANTIBODIES AND METHODS OF USE

MULTIFUNCTIONAL MOLECULES BINDING TO TCR AND USES THEREOF

COMBINATION OF ANTI-CD40 ANTIBODY AND IL-15 FOR TREATING CANCER

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

CD20-PD1 BINDING MOLECULES AND METHODS OF USE THEREOF

AGONISTIC CD40 ANTIBODIES AS IMMUNE STIMULATORY AGENTS

Antibodies Directed to TIE-2 and Methods of Use

MODULATION OF WNT SIGNALLING IN PULMONARY DISORDERS

METHOD OF TREATING BONE CANCERS

HINGE-MODIFIED BISPECIFIC ANTIBODIES

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

ANTIBODIES CAPABLE OF BINDING TO OX40, VARIANTS THEREOF AND USES THEREOF

Multivalent and Multispecific DR5-Binding Fusion Proteins

TREM2 ANTIGEN BINDING PROTEINS AND USES THEREOF

Method for making pluripotent stem cells

MOLECULES FOR MODULATING THE IMMUNE SYSTEM AND USES THEREOF

METHODS AND COMPOSITIONS FOR ENHANCING THE CYTOTOXICITY OF GAMMA/DELTA-T CELLS

USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENT

CYTOSKELETAL TENSION REGULATORS AND FAS LIGAND-COMBINATION COMPOSITIONS AND METHODS OF TREATMENT USING THE SAME

Bispecific T cell Engagers

CD123 BINDING PROTEINS AND RELATED COMPOSITIONS AND METHODS

IGFR-L1 ANTIBODIES AND USES THEREOF

Compositions and Methods for Treatment and Prevention of Misfolded Proteins

GENE SIGNATURE PREDICTING TERTIARY LYMPHOID STRUCTURES CONTAINING B CELLS

ANTIGEN-BINDING POLYPEPTIDES DIRECTED AGAINST CD38

ANTIBODIES TO CD40

COMPOSITIONS AND METHODS FOR AUGMENTING ANTIBODY MEDIATED RECEPTOR SIGNALING

BIOMARKERS FOR CD40 AGONIST THERAPY

METHODS OF EFFECTING A HEMODYNAMIC CHANGE BY ADMINISTERING AN ANTI-NPR1 ANTIBODY

TIE2-BINDING AGENTS AND METHODS OF USE

DUAL RECEPTOR ANTAGONISTIC ANTIGEN-BINDING PROTEINS AND USES THEREOF

DRUG FOR PREVENTING, ALLEVIATING OR TREATING MUCOSAL ADHESION AND USE THEREOF

ANTI-OX40 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF

POLYPEPTIDE COMPLEXES WITH IMPROVED STABILITY AND EXPRESSION

ANTI-NPR1 ANTIBODIES AND USES THEREOF

Anti-Trkb Monoclonal Antibodies And Methods Of Use

Anti-SIRPα antibodies and methods of use thereof

PD-1 ANTIBODIES, POLYPEPTIDES AND USES THEREOF

Method and Compositions for Inducing Differentiation of Myeloid Derived Suppressor Cell to Treat Cancer and Infectious Diseases

ANTI-MERTK ANTIBODIES AND METHODS OF USE THEREOF

RECEPTOR TYROSINE KINASE AGONIST, COMPOSITION FOR CELL CULTURE MEDIUM, AND UNDIFFERENTIATED MAINTENANCE COMPOSITION

TRISPECIFIC AND/OR TRIVALENT BINDING PROTEINS

TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF

ANTI-KLB ANTIBODIES AND USES

ENGINEERED ANTIBODY FC VARIANTS FOR ENHANCED SERUM HALF LIFE

ANTIGEN-BINDING MOLECULE COMPRISING ALTERED ANTIBODY VARIABLE REGION BINDING CD3 AND CD137

ONCOLYTIC VIRUS AND USES THEREOF

ANTI-PD-1×4-1BB BINDING PROTEINS

SKIN TARGETED IMMUNOTOLERANCE

AGONISTIC TNF RECEPTOR BINDING AGENTS

TIE2 AGONISTIC ANTIBODIES AND USES THEREOF

NOVEL WNT AGONIST ANTIBODIES AND THERAPEUTIC USES THEREOF

CONNEXIN (Cx)43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

VARIANT IgG FC POLYPEPTIDES AND USES THEREOF

PANCREAS TARGETED THERAPEUTICS AND USES THEREOF

ANTI-CD40 ANTIBODY AND USE THEREOF

METHODS FOR EXPANSION OR DEPLETION OF T-REGULATORY CELLS

BINDING MOLECULES THAT BIND CD137 AND PD-L1

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

Novel TNFR2 Binding Molecules

OX40 AGONIST AND USE THEREOF

Antibodies to programmed cell death protein 1 that are PD-1 agonists

AGONIST ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF

Adenovirus armed with bispecific T cell activator

LAG-3 AND PD-1/LAG-3-ANTIBODIES

MESOTHELIN-TARGETED CD40 AGONISTIC MULTISPECIFIC ANTIBODY CONSTRUCTS FOR THE TREATMENT OF SOLID TUMORS

MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS

COMPOSITIONS AND METHODS FOR INCREASING TRANSPORT INTO THE BRAIN

ANTI-VISTA CONSTRUCTS AND USES THEREOF

COMBINATION THERAPIES WITH ANTI CD40 ANTIBODIES

Variant IgG Fc polypeptides and uses thereof

PANCREAS TARGETED THERAPEUTICS AND USES THEREOF

ANTI-TIGIT ANTIBODIES AND METHODS OF USE

MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND METHODS OF USING THE SAME

ANTIBODIES BINDING CD40 AND PD-L1 AND USES THEREOF

Anti-SIRP-alpha antibodies and methods of use thereof

Antibodies to programmed cell death protein 1

ANTI-PD-1 ANTIBODY-ATTENUATED IL-2 IMMUNOCONJUGATES AND USES THEREOF

Single domain antibodies targeting CD1d

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

BISPECIFIC ANTIBODY WHICH BINDS TO CD40 AND EpCAM

MULTIVALENT BINDING MOLECULES

MEDICINAL COMPOSITION USABLE FOR PREVENTING AND/OR TREATING BLOOD COAGULATION FACTOR IX ABNORMALITY, COMPRISING MULTISPECIFIC ANTIGEN BINDING MOLECULE REPLACING FUNCTION OF BLOOD COAGULATION FACTOR VIII

IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES

MUSK ACTIVATION

ANTI-ICOS AGONIST ANTIBODIES AND USES THEREOF

ENGINEERED iPSC AND ARMED IMMUNE EFFECTOR CELLS

ANTIBODIES AND METHODS OF USE

ANTIBODIES TO CD40 WITH ENHANCED AGONIST ACTIVITY

Bispecific CD137-binding antibodies for T-cell activation

SELF-ANTIGEN SPECIFIC T-CELLS AS VACCINES FOR AUGMENTING ENGRAFTMENT AND STABILITY OF AUTOLOGOUS TRANSFER

ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-CD19 ANTIBODIES

AGONISTIC ANTI-IL-2R ANTIBODIES AND METHODS OF USE

ENGINEERED FCRIIB SELECTIVE IGG1 FC VARIANTS AND USES THEREOF

AGONISTIC CD40 ANTIBODIES

Method of treating cancer using CD137 antibodies and PD-1 antagonists

FACTOR X BINDERS ENHANCING FX ACTIVATION

DYSFUNCTIONAL ANTIGEN-SPECIFIC CD8+ T CELLS IN THE TUMOR MICROENVIRONMENT

Multivalent and multispecific 41BB-binding proteins

TUMOR-TARGETED AGONISTIC CD28 ANTIGEN BINDING MOLECULES

ANTI-CD40 ANTIBODIES AND METHODS OF USE

ANTIBODIES AND METHODS OF USE THEREOF

ANTIBODIES AND METHODS OF USE THEREOF

ICOS TARGETING FOR NEUROPATHIC PAIN RELIEF

TRISPECIFIC BINDERS

NATRIURETIC PEPTIDE RECEPTOR 1 ANTIBODIES AND METHODS OF USE

COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES

ANTIBODY SUBSTITUTING FOR FUNCTION OF BLOOD COAGULATION FACTOR VIII

COMBINATION THERAPY WITH FAP-TARGETED CD40 AGONISTS

COMPOSITIONS AND METHODS FOR TREATING CANCER

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER

ANTI-IDIOTYPIC ANTIBODIES TO ROR1-TARGETED BINDING DOMAINS AND RELATED COMPOSITIONS AND METHODS

PHARMACEUTICAL COMPOSITION COMPRISING CELL EXPRESSING CHIMERIC RECEPTOR

ANTI-TREM2 ANTIBODIES AND METHODS OF USE THEREOF

COMPOSITIONS AND METHODS FOR IN VIVO GENERATION OF CAR EXPRESSING CELLS

MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES

NOVEL ANTI-CD137 ANTIBODIES AND USES THEREOF

HUMANIZED ANTIBODIES WITH ULTRALONG COMPLEMENTARY DETERMINING REGIONS

Anti-coagulation factor XI antibodies

ANTI-CD277 ANTIBODIES AND USES THEREOF

Anti-CD73 antibodies and use thereof

ANTI-CD137 ANTIBODIES

ANTI-LAG-3 ANTIBODIES

Monoclonal Antibodies to Programmed Death 1 (PD-1)

NEUROPILIN-1 VARIANT ANTIBODIES AND METHODS OF USE

BINDING PROTEINS AND METHODS OF USE THEREOF

ANTI-OX40 ANTIBODY AND USES THEREOF

Agonistic anti-IL-2R antibodies and methods of use

MULTIFUNCTIONAL IMMUNOTHERAPEUTIC MONOCLONAL ANTIBODY COMPLEXES AND CONJUGATES

ANTIBODY-BOUND NANOPARTICLES

Anti-transferrin receptor antibodies with tailored affinity

MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE HAVING ALTERNATIVE FUNCTION TO FUNCTION OF BLOOD COAGULATION FACTOR VIII

PD-1 AGONIST MULTIMERIC BINDING MOLECULES

TUMOR NECROSIS FACTOR (TNF) SUPERFAMILY RECEPTOR IGM ANTIBODIES AND USES THEREOF